Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Complementary medicine use common among patients on TKIs

Publish date:: April 24, 2019

Key clinical point: Many patients receiving tyrosine kinase inhibitors (TKIs) are taking complementary therapies or eating foods that interfere with TKI metabolism.

Major finding: More than one-third of patients with chronic myeloid leukemia (34%) reported taking a complementary medicine.

Study details: A survey of 61 patients with chronic myeloid leukemia (CML) who were also taking a TKI.

Disclosures: The investigators reported having no conflicts of interest.

Citation:

REPORTING FROM BSH 2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CML

Survey quantifies COVID-19’s impact on oncology,

Baseline gene expression predicts TKI response in CML,

Inotuzumab/bosutinib treat R/R Ph+ ALL, CML in blast phase,

Complementary medicine use common among patients on TKIs,

Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.